ITP Drug Pipeline: FcRn, TPO & B Cell — PatSnap Eureka
Immune Thrombocytopenia Drug Pipeline: FcRn Inhibitors, TPO Agonists & B Cell Approaches
Three mechanistically distinct drug classes — FcRn antagonists, TPO receptor agonists, and B cell-directed agents — are now competing and converging as combination strategies in the ITP therapeutic landscape. Explore the patent and literature signals shaping this field.
Autoimmune Platelet Destruction: The Molecular Drivers of ITP
ITP (immune thrombocytopenia) is an autoimmune disorder in which self-reactive IgG antibodies mediate platelet destruction through Fc receptor–dependent mechanisms. The neonatal Fc receptor (FcRn/FCGRT) acts as a central mediator of IgG homeostasis: by recycling IgG from intracellular sorting endosomes to the cell surface, FcRn extends the half-life of anti-platelet autoantibodies. argenx BV patents describe this mechanism as the core rationale for FcRn antagonism — blocking FcRn disrupts the antibody salvage pathway, accelerating IgG clearance including the pathogenic ITP-associated antibodies.
On the thrombopoiesis side, the TPO receptor (c-Mpl/MPL) and its downstream JAK-STAT signaling pathway represent the dominant platelet production axis. Sichuan Clover Biopharmaceuticals and historical filings from Novartis and Genentech describe TPO receptor agonism as promoting megakaryocyte differentiation, proplatelet formation, and platelet release from bone marrow.
For B cell–directed approaches, BAFF-R (B cell activating factor receptor) and CD20 (target of rituximab/obinutuzumab) are identified as key nodes. A Novartis patent (CN 2025) directly identifies elevated serum BAFF as a feature of untreated ITP patients and rituximab-resistant patients, and proposes BAFF-R inhibition with ianalumab as first- or second-line ITP therapy. A Shanghai Synvida Biotechnology filing (EP 2024) notes that approximately one-third of ITP patients respond poorly to pharmacological treatment and progress to chronic ITP with high mortality.
The PatSnap life sciences intelligence platform enables R&D teams to map these mechanistic pathways across patent and literature datasets to identify competitive white space and combination therapy opportunities.
Five Mechanistically Distinct Drug Classes in the ITP Pipeline
From established TPO receptor agonists to next-generation FcRn antagonists and precision B cell-directed agents, the ITP pipeline spans multiple mechanistic classes with distinct IP landscapes.
FcRn Antagonists: Accelerating Pathogenic IgG Clearance
FcRn antagonists compete with endogenous IgG for FcRn binding, disrupting the recycling salvage pathway and accelerating IgG catabolism. In ITP, this reduces circulating anti-platelet autoantibody titers, thereby diminishing antibody-mediated platelet destruction. argenx BV describes efgartigimod (ARGX-113) as a high-affinity FcRn antagonist derived from a human IgG1 Fc fragment. UCB Biopharma SRL independently filed patents for a separate anti-FcRn antibody, specifying dosing of 1–30 mg/kg across 1–5 doses over 1–12 weeks.
Clinical-StageTPO-R Agonists: Stimulating Platelet Production
TPO-R agonists stimulate the c-Mpl receptor on megakaryocyte progenitors, driving megakaryocyte maturation, proplatelet formation, and platelet shedding into the circulation. Three agents are approved: romiplostim, eltrombopag, and avatrombopag. Their long-term response rate is noted as 40–50%. Sichuan Clover Biopharmaceuticals discloses a novel bifunctional fusion protein with six TPOR binding domains and a p75 TNF receptor domain, suggesting dual anti-inflammatory and pro-thrombopoietic activity.
3 Agents ApprovedB Cell Depletion & BAFF-R Targeting
B cells are the cellular source of anti-platelet IgG autoantibodies in ITP. CD20-targeting agents (rituximab, obinutuzumab) deplete mature B cells. A Novartis patent (CN 2025) proposes targeting BAFF-R with ianalumab, arguing that elevated BAFF drives pathological B cell survival, autoantibody production, and resistance to rituximab. BAFF-R signaling is described as critical to B cell effector function, antibody production, isotype class switching, and B cell proliferation, maturation, and survival.
Emerging / Second-LineBTK Inhibition: Convergent B Cell & Macrophage Signaling
Rilzabrutinib (PRN1008), a covalent reversible BTK inhibitor developed by Principia Biopharma (now Sanofi), interferes with B cell receptor signaling required for autoantibody-producing B cell activation, and may also suppress Fcγ receptor–mediated platelet destruction by macrophages. A CN 2025 filing specifies enrollment criteria referencing platelet counts <33,000/μL and prior therapy requirements including splenectomy, IVIG, and corticosteroids, indicating second-line or later positioning.
Clinical-StageEffector-Deficient Anti-CD32a Antibodies: Blocking Immune Complex–Driven Platelet Destruction
FcγRIIa (CD32a) is an activating Fc receptor on platelets and phagocytes that mediates immune complex–dependent platelet destruction in ITP. Adventist Health System/Sunbelt developed effector-deficient anti-CD32a monoclonal antibodies (AT-10, MDE-8 variants with IgG1 E269R or IgG2 N297A mutations) to block this pathway without triggering infusion-related reactions seen with effector-competent anti-CD32a mAbs. Preclinical data from CD32A transgenic mice are cited in retrieved filings. Learn more about PatSnap's IP analytics capabilities for antibody engineering landscapes.
PreclinicalITP Drug Pipeline: Key Data Visualisations
Patent filing distributions and development stage profiles derived from retrieved patent and literature records, analysed via PatSnap Eureka.
ITP Patent Filings by Therapeutic Modality
FcRn antagonists (argenx + UCB) represent the most patent-densely protected ITP-specific mechanism in this dataset, with 11 distinct jurisdiction filings retrieved.
Patent Assignee Distribution — ITP Dataset
argenx BV is the most prolific single assignee for ITP-specific drug IP in this dataset, representing the dominant share of FcRn-focused filings.
Key Patent Assignees in the ITP Drug Pipeline
Patent activity clearly dominates over academic literature in this dataset, reflecting active commercial IP filing across multiple therapeutic classes and jurisdictions.
| Assignee | Country | Target / Drug | Jurisdictions | Stage Signal |
|---|---|---|---|---|
| argenx BV / argenx BVBA | Belgium | FcRn / efgartigimod (ARGX-113) | AU, CA, IL, ID, MX, SG, JP, BR, WO | Clinical-Stage |
| Principia Biopharma Inc. (Sanofi) | US | BTK / rilzabrutinib (PRN1008) | MX, CO, BR, CN | Clinical-Stage |
| UCB Biopharma SRL | Belgium/UK | FcRn / anti-FcRn antibody | AU, IL | Clinical-Stage |
| Novartis AG | Switzerland | BAFF-R / ianalumab | CN (2025), NZ (historical) | Emerging |
Track ITP IP Filings Across Jurisdictions
Monitor new patent filings from argenx, Novartis, Principia/Sanofi and emerging biotech players in real time with PatSnap Analytics.
Combination Therapy: The Emerging Commercial Paradigm in ITP
Patent filings from argenx, Principia/Sanofi, and Novartis all explicitly claim or reference combination use with standard-of-care agents including TPO-RAs, signalling a convergent multi-mechanism treatment strategy.
FcRn Inhibitor + TPO-RA Combination
Multiple argenx BV patents explicitly disclose efgartigimod administered "optionally in combination with standard-of-care ITP treatment," with standard-of-care defined to include "corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists." This represents a patent-protected combination claim spanning two mechanistic classes — pathogenic antibody elimination (FcRn antagonism) plus platelet production stimulation (TPO-RA).
BTK Inhibitor + TPO-RA Combination
A retrieved 2025 CN Principia Biopharma filing explicitly lists combination with romiplostim, eltrombopag, or avatrombopag as a treatment strategy for rilzabrutinib, indicating that BTK + TPO-RA combinations are being explored clinically or near-clinically. This signals convergence between B cell signaling inhibition and platelet production stimulation as a dual-mechanism approach.
What the ITP Patent Landscape Means for Drug Developers & IP Strategists
FcRn antagonism is the most patent-densely protected ITP-specific mechanism in this dataset, with argenx BV holding a broad multi-jurisdictional portfolio around efgartigimod for ITP. IP strategists evaluating freedom-to-operate in this space must navigate an active and overlapping claim landscape, particularly given UCB Biopharma's independent anti-FcRn antibody filings in overlapping jurisdictions.
The TPO-RA space is mature but structurally evolving. Three agents are cited as approved within retrieved results, yet novel multi-domain fusion protein architectures (Sichuan Clover) and ex vivo patient selection platforms (Tufts College) signal continued innovation. Developers of next-generation TPO-RAs will need to demonstrate differentiation in durability, safety, or patient subgroup performance beyond the 40–50% long-term response rate noted for existing agents.
B cell–directed approaches face a two-layer IP challenge. CD20 antibodies (rituximab, obinutuzumab) are established but associated with acute thrombocytopenia risk, while BAFF-R targeting (ianalumab/Novartis) represents an emerging second-line strategy for rituximab-refractory ITP with a freshly filed (2025) patent, suggesting early IP landscape development. The European Medicines Agency and FDA regulatory frameworks will shape how these agents are positioned in clinical practice.
Secondary thrombocytopenia contexts (myelofibrosis-associated, chemotherapy-induced) represent a significant parallel opportunity. Keros Therapeutics and Celgene/BMS filings on ActRII signaling inhibitors and Sichuan Clover's bispecific TNF/TPOR molecule suggest that mechanisms validated in ITP are being actively extended to secondary thrombocytopenia settings. See how PatSnap customers use patent intelligence to identify these adjacent market opportunities.
Evidence of Clinical Translation Across ITP Drug Modalities
Retrieved results contain several signals of clinical translation, though direct trial outcome data are not present in the dataset. No retrieved results contain explicit clinical trial phase designations or published efficacy endpoints from controlled trials.
FcRn Antagonism: Multi-Jurisdiction Active Filings Signal Commercial Maturation
The argenx AU patent (2024) explicitly states that "at present three TPO-R agonists have been approved for use in the treatment of ITP," and positions efgartigimod as a complementary agent — suggesting the patent was filed in a context where clinical ITP data for efgartigimod already existed or was being generated. Multiple filings in active jurisdictions (AU active, JP active) further signal commercial maturation. WHO INN registration data may provide additional context on development stage.
Active AU + JP jurisdictionsEltrombopag in Refractory Aplastic Anemia: Proof of Concept Beyond ITP
A retrieved paper from Hacettepe University (2013) reports eltrombopag producing hematological responses in severe refractory aplastic anemia, citing a pilot trial in 25 cases with 11 responses including trilineage recovery. This establishes proof of concept for TPO-RA activity in bone marrow failure beyond ITP, supporting the broader applicability of TPO receptor agonism across thrombocytopenic conditions.
25 cases, 11 responses including trilineage recoveryRilzabrutinib CN 2025: Detailed Trial Eligibility Criteria Signal Active Development
A CN 2025 filing specifies detailed eligibility criteria: platelet count <33,000/μL on two occasions within 15 days, history of response to at least one prior therapy including splenectomy, IVIG, corticosteroids, anti-D immunoglobulin, or immunosuppressants. This level of clinical specificity is consistent with active or planned clinical trial enrollment criteria, positioning rilzabrutinib as a second-line or later agent.
Platelet count <33,000/μL eligibility thresholdPersonalised TPO-RA Response Prediction: IND-Enabling Translational Tool
Tufts College patents (WO 2021, US 2023) describe a 3D bone marrow model using silk fibroin sponges with patient-derived megakaryocyte progenitors for generating patient-specific predictions of TPO-RA in vivo efficacy. This represents an IND-enabling or clinical trial enrichment tool, signalling prospective clinical translation planning and the emergence of personalised medicine approaches in ITP treatment selection. Explore related life sciences IP analytics capabilities.
Silk fibroin 3D scaffold + patient megakaryocyte progenitorsITP Drug Pipeline — Key Questions Answered
FcRn antagonists compete with endogenous IgG for FcRn binding, disrupting the recycling salvage pathway and accelerating IgG catabolism. In ITP, this reduces circulating anti-platelet autoantibody titers, thereby diminishing antibody-mediated platelet destruction. argenx BV describes efgartigimod (ARGX-113) as a high-affinity FcRn antagonist derived from a human IgG1 Fc fragment active at the hFcRn receptor.
Retrieved patent data explicitly identifies three approved TPO-R agonists for ITP treatment: romiplostim, eltrombopag, and avatrombopag. These agents stimulate the c-Mpl receptor on megakaryocyte progenitors, driving megakaryocyte maturation and platelet production. Their long-term response rate is noted as 40–50%.
A Novartis patent (CN 2025) identifies elevated serum BAFF as a feature of untreated ITP patients and rituximab-resistant patients. Elevated BAFF drives pathological B cell survival, autoantibody production, and resistance to rituximab. The patent proposes BAFF-R inhibition with ianalumab as a first- or second-line ITP therapy, noting that elevated BAFF impairs rituximab-induced ADCC, providing mechanistic rationale for sequencing BAFF-R inhibition after anti-CD20 failure.
Rilzabrutinib (PRN1008) is a covalent reversible BTK inhibitor developed by Principia Biopharma. In ITP, BTK inhibition interferes with B cell receptor signaling required for autoantibody-producing B cell activation, and may also suppress Fcγ receptor–mediated platelet destruction by macrophages. A CN 2025 filing specifies detailed eligibility criteria (platelet count less than 33,000/μL on two occasions within 15 days, history of response to at least one prior therapy) consistent with active or planned clinical trial enrollment, indicating clinical-stage development.
Retrieved patent filings signal several converging combination strategies. Multiple argenx BV patents explicitly disclose efgartigimod administered optionally in combination with standard-of-care ITP treatment including corticosteroids, immunosuppressants, and TPO-R agonists. A 2025 CN Principia Biopharma filing explicitly lists combination with romiplostim, eltrombopag, or avatrombopag as a treatment strategy for rilzabrutinib. Novartis patents also reference BAFF-R inhibition after rituximab failure as an emerging precision B cell depletion strategy.
A Shanghai Synvida Biotechnology filing (EP 2024) notes that approximately one-third of ITP patients respond poorly to pharmacological treatment and progress to chronic ITP with high mortality. Additionally, existing approved TPO-R agonists (romiplostim, eltrombopag, avatrombopag) have a noted long-term response rate of 40–50%, indicating a significant unmet need for durable treatment options.
Still have questions about the ITP drug pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About ITPAccelerate Your ITP Drug Pipeline Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search FcRn, TPO-R, BAFF-R, BTK, and CD32a patent landscapes in one platform.
References
- Compositions and methods for treating immune thrombocytopenia — argenx BV, 2021, ID [Patent]
- Compositions and methods for treating immune thrombocytopenia — argenx BV, 2021, IL [Patent]
- Compositions and methods for treating immune thrombocytopenia — argenx BV, 2019, CA [Patent]
- Compositions and methods for treating immune thrombocytopenia — argenx BV, 2020, AU [Patent]
- Compositions and methods for treating immune thrombocytopenia — argenx BV, 2024, AU [Patent]
- Compositions and methods for treating immune thrombocytopenia — argenx BVBA, 2020, SG [Patent]
- Compositions and methods for treating immune thrombocytopenia — Cousin, Thierry / argenx BV, 2019, WO [Patent]
- Compositions and methods for treating immune thrombocytopenia — argenx BVBA, 2024, JP [Patent]
- Method for the treatment of immune thrombocytopenia — UCB Biopharma SRL, 2020, IL [Patent]
- Method for the treatment of immune thrombocytopenia — UCB Biopharma SRL, 2020, IL [Patent]
- Method for the treatment of immune thrombocytopenia — UCB Biopharma SRL, 2020, AU [Patent]
- Methods for treating immune thrombocytopenia by administering PRN1008 — Principia Biopharma Inc., 2022, MX [Patent]
- Methods for treating ITP through administration of rilzabrutinib — Principia Biopharma Inc., 2025, CN [Patent]
- Methods for treating immune thrombocytopenia through administration of PRN1008 — Principia Biopharma Inc., 2022, BR [Patent]
- TPO mimetic fusion proteins and methods of use — Sichuan Clover Biopharmaceuticals, Inc., 2024, US [Patent]
- TPO mimetic fusion proteins and methods of use — Sichuan Clover Biopharmaceuticals, Inc., 2023, WO [Patent]
- Systems and methods for assessing patient-specific response to thrombopoietin-receptor agonists — Trustees of Tufts College, 2023, US [Patent]
- Systems and methods for assessing patient-specific response to thrombopoietin-receptor agonists — Trustees of Tufts College, 2021, WO [Patent]
- Treatment of immune thrombocytopenia (ITP) — Novartis, 2025, CN [Patent]
- Effector-deficient Anti-CD32a antibodies — Adventist Health System/Sunbelt Inc., 2017, EP [Patent]
- Effector-deficient anti-CD32a antibodies — Adventist Health System/Sunbelt Inc., 2019, US [Patent]
- Effector-deficient Anti-CD32a antibodies — Adventist Health System/Sunbelt Inc., 2017, AU [Patent]
- Product and method for treating thrombocytopenia — Shanghai Synvida Biotechnology Co. Ltd., 2024, EP [Patent]
- The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia — Hacettepe University, 2013 [Paper]
- Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia — Otto-von-Guericke University, 2022 [Paper]
- National Institutes of Health (NIH) — ITP and autoimmune hematology resources
- U.S. Food and Drug Administration (FDA) — Drug approvals and hematology guidance
- European Medicines Agency (EMA) — ITP therapeutic guidelines and approvals
- NCBI PubMed — JAK-STAT signaling and megakaryocyte biology literature
- World Health Organization (WHO) — International nonproprietary names and drug development tracking
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a targeted set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.